Price (delayed)
$29.57
Market cap
$2.41B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$4.17
Enterprise value
$2.41B
Beam Therapeutics is a biotechnology company committed to establishing the leading, fully integrated platform for precision genetic medicines. To achieve this vision, Beam has assembled a platform that includes a
There are no recent dividends present for BEAM.
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.